Despite the major therapeutic improvement of ALK TKI in NSCLC, disease progression after initial benefit has been described due to the development of resistance mechanisms with clinically progressive disease and a variable range of aggressiveness [23-25]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.